Interleukin-12 alters helper T-cell subsets and antibody profiles induced by the mucosal adjuvant cholera toxin.
We have shown that systemic administration of rmIL-12 could trigger Th1-type responses to a protein antigen delivered orally with CT as mucosal adjuvant. The most striking finding was that IL-12 could retain its regulatory effects when orally administered and could redirect the immune response to the oral vaccine toward a Th1-type. However, regulation by orally administered IL-12 differed from parenteral treatment with IL-12 since only the latter treatment affected mucosal S-IgA responses. These findings have important implications for the development of mucosal vaccines that induce the desired immune response.
Marinaro
M
M
Department of Microbiology, University of Alabama at Birmingham Medical Center 35294-2170, USA.
Boyaka
P N
PN
Jackson
R J
RJ
Finkelman
F D
FD
Kiyono
H
H
McGhee
J R
JR
D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000818:Animals; D002772:Cholera Toxin / Q000494:pharmacology; D018928:Immunity, Mucosal; D018664:Interleukin-12 / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D013745:Tetanus Toxoid / Q000276:immunology
D000276:Adjuvants, Immunologic; D013745:Tetanus Toxoid; D018664:Interleukin-12; D002772:Cholera Toxin